PURPOSE: To determine clinicopathological risk factors associated with lymph node metastasis in endometrial cancer (EC). METHODS: Clinicopathological data of patients who underwent comprehensive surgical staging for clinical early stage EC between 2001 and 2010 at Hacettepe University Hospital was retrospectively reviewed. RESULTS: Two hundred and sixty-one patients were included. There were 26 patients (10.0%) with lymph node metastasis. Of these, 14 (5.4%) had pelvic lymph node metastasis, 8 (3.1%) had both pelvic and paraaortic lymph node metastasis, and 4 (1.5%) had isolated paraaortic metastasis. Univariate analysis revealed tumor size >2 cm, type II cancer, grade III histology, cervical stromal invasion, deep myometrial invasion, positive peritoneal cytology, adnexal involvement, serosal involvement, and presence of lymphovascular space involvement (LVSI) as significant clinicopathological factors associated with retroperitoneal lymph node metastasis. For paraaortic metastasis either isolated or with pelvic lymph node metastasis, significant factors were grade III disease, cervical stromal invasion, deep myometrial invasion, positive peritoneal cytology, adnexal involvement, serosal involvement, pelvic lymph node metastasis, and presence of LVSI. The only factor associated with isolated paraaortic lymph node metastasis was LVSI. Multivariate analysis revealed LVSI as the only independent factor for both retroperitoneal and paraaortic lymph node metastasis (odds ratio 14.9; 95% confidence interval 3.8-59.0; p < 0.001, and odds ratio 20.9; 95% confidence interval 1.9-69.9; p = 0.013, respectively). CONCLUSION: Lymphovascular space involvement is the sole predictor of lymph node metastasis in EC. Therefore, LVSI status should be requested from the pathologist during frozen examination whenever possible to consider when a decision to perform or omit lymphadenectomy is made.
PURPOSE: To determine clinicopathological risk factors associated with lymph node metastasis in endometrial cancer (EC). METHODS: Clinicopathological data of patients who underwent comprehensive surgical staging for clinical early stage EC between 2001 and 2010 at Hacettepe University Hospital was retrospectively reviewed. RESULTS: Two hundred and sixty-one patients were included. There were 26 patients (10.0%) with lymph node metastasis. Of these, 14 (5.4%) had pelvic lymph node metastasis, 8 (3.1%) had both pelvic and paraaortic lymph node metastasis, and 4 (1.5%) had isolated paraaortic metastasis. Univariate analysis revealed tumor size >2 cm, type II cancer, grade III histology, cervical stromal invasion, deep myometrial invasion, positive peritoneal cytology, adnexal involvement, serosal involvement, and presence of lymphovascular space involvement (LVSI) as significant clinicopathological factors associated with retroperitoneal lymph node metastasis. For paraaortic metastasis either isolated or with pelvic lymph node metastasis, significant factors were grade III disease, cervical stromal invasion, deep myometrial invasion, positive peritoneal cytology, adnexal involvement, serosal involvement, pelvic lymph node metastasis, and presence of LVSI. The only factor associated with isolated paraaortic lymph node metastasis was LVSI. Multivariate analysis revealed LVSI as the only independent factor for both retroperitoneal and paraaortic lymph node metastasis (odds ratio 14.9; 95% confidence interval 3.8-59.0; p < 0.001, and odds ratio 20.9; 95% confidence interval 1.9-69.9; p = 0.013, respectively). CONCLUSION: Lymphovascular space involvement is the sole predictor of lymph node metastasis in EC. Therefore, LVSI status should be requested from the pathologist during frozen examination whenever possible to consider when a decision to perform or omit lymphadenectomy is made.
Authors: Ricardo dos Reis; Jennifer K Burzawa; Audrey T Tsunoda; Masayoshi Hosaka; Michael Frumovitz; Shannon N Westin; Mark F Munsell; Pedro T Ramirez Journal: Int J Gynecol Cancer Date: 2015-09 Impact factor: 3.437
Authors: Casper Reijnen; Joanna IntHout; Leon F A G Massuger; Fleur Strobbe; Heidi V N Küsters-Vandevelde; Ingfrid S Haldorsen; Marc P L M Snijders; Johanna M A Pijnenborg Journal: Oncologist Date: 2019-06-11
Authors: S Jaishankar; P M Pifer; R Bhargava; A Keller; H B Musunuru; A K Patel; P Sukumvanich; M Boisen; J L Berger; S Taylor; M Courtney-Brooks; A Olawaiye; J Lesnock; R Edwards; J A Vargo; S Beriwal Journal: Clin Oncol (R Coll Radiol) Date: 2022-03-06 Impact factor: 4.925
Authors: Casper Reijnen; Nicole Cm Visser; Jenneke C Kasius; Dorry Boll; Peggy M Geomini; Huy Ngo; Dennis Van Hamont; Brenda M Pijlman; Maria Caroline Vos; Johan Bulten; Marc Plm Snijders; Leon Fag Massuger; Johanna Ma Pijnenborg Journal: J Gynecol Oncol Date: 2019-09 Impact factor: 4.401
Authors: Ashley E Veade; Jonathan Foote; Jessie Ehrisman; Gloria Broadwater; Brittany A Davidson; Paula S Lee; Angeles Alvarez Secord; Andrew Berchuck; Laura J Havrilesky Journal: World J Surg Oncol Date: 2019-05-10 Impact factor: 2.754